|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 27/00 | (2006.01) |
| (11) | Number of the document | 1933869 |
| (13) | Kind of document | T |
| (96) | European patent application number | 06813945.0 |
| Date of filing the European patent application | 2006-08-30 | |
| (97) | Date of publication of the European application | 2008-06-25 |
| (45) | Date of publication and mention of the grant of the patent | 2009-10-14 |
| (46) | Date of publication of the claims translation | 2010-01-25 |
| (86) | Number | PCT/US2006/033840 |
| Date | 2006-08-30 |
| (87) | Number | WO 2007/027761 |
| Date | 2007-03-08 |
| (30) | Number | Date | Country code |
| 713792 P | 2005-09-01 | US | |
| 837312 P | 2006-08-11 | US |
| (72) |
CUA, Daniel, J., US
KASTELEIN, Robert, A., US
TSAI, Van, T., US
CASPI, Rachel, US
SILVER, Phyllis, US
LUGER, Dror, US
|
| (73) |
MERCK SHARP & DOHME CORP.,
126 East Lincoln Avenue, Rahway, New Jersey 07065,
US
The Government of the United States of America as represented by The Secretary of the Department of Health and Human S, National Institutes of Health Office of Technology Transfer Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804, US |
| (74) |
Genė Ona SRUOGIENĖ,
UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius,
LT
|
| (54) | IL-23 ir IL-17 antagonistų panaudojimas autoimuninei akių uždegiminei ligai gydyti |
| USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE |
| Payment date | Validity (years) | Amount | |
| 2012-08-03 | 7 | 560.00 LTL |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2012-10-24 |